Megan M Dupuis1, Barry Paul2, Gavin Loitsch2, Parker Mathews2, Daniel Feinberg2, Ian Barak3, Zhiguo Li3, Sascha A Tuchman4, Yubin Kang2. 1. Hematology/Oncology Fellowship Program, MD Anderson Cancer Center, The University of Texas, Houston, TX. 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC. 3. Biostatistics Shared Resource, Duke Cancer Institute, Duke University Medical Center, Durham, NC. 4. Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Abstract
PURPOSE: We performed a retrospective chart review on 393 patients with multiple myeloma (MM) to determine the utility of the gamma gap (GG). METHODS: We calculated the difference between a patient's total serum protein and albumin as a point-of-care test for assessing disease status in MM. RESULTS: GG is highly correlated with the level of M-spike, and the change in GG correlates with myeloma treatment response. In addition, fitted linear models were established that allow for the calculation of M-protein level from the GG within hours from blood draw. CONCLUSION: Our study has important implications in the care of MM, particularly in countries/areas with limited resources.
PURPOSE: We performed a retrospective chart review on 393 patients with multiple myeloma (MM) to determine the utility of the gamma gap (GG). METHODS: We calculated the difference between a patient's total serum protein and albumin as a point-of-care test for assessing disease status in MM. RESULTS: GG is highly correlated with the level of M-spike, and the change in GG correlates with myeloma treatment response. In addition, fitted linear models were established that allow for the calculation of M-protein level from the GG within hours from blood draw. CONCLUSION: Our study has important implications in the care of MM, particularly in countries/areas with limited resources.
Authors: Joseph Mikhael; Nofisat Ismaila; Matthew C Cheung; Caitlin Costello; Madhav V Dhodapkar; Shaji Kumar; Martha Lacy; Brea Lipe; Richard F Little; Anna Nikonova; James Omel; Namrata Peswani; Anca Prica; Noopur Raje; Rahul Seth; David H Vesole; Irwin Walker; Alexander Whitley; Tanya M Wildes; Sandy W Wong; Tom Martin Journal: J Clin Oncol Date: 2019-04-01 Impact factor: 44.544
Authors: Jerry A Katzmann; Maria A V Willrich; Mindy C Kohlhagen; Robert A Kyle; David L Murray; Melissa R Snyder; S Vincent Rajkumar; Angela Dispenzieri Journal: Clin Chem Date: 2014-12-01 Impact factor: 8.327
Authors: Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin Journal: J Clin Oncol Date: 2005-04-04 Impact factor: 44.544
Authors: Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau Journal: Lancet Oncol Date: 2016-08 Impact factor: 41.316